ST6GAL2 antibody (C-Term)

Catalog No. ABIN1881842

The Rabbit Polyclonal anti-ST6GAL2 antibody has been validated for WB. It is suitable to detect ST6GAL2 in samples from Human. There are 5+ publications available.

Quick Overview for ST6GAL2 antibody (C-Term) (ABIN1881842)

Target: ST6GAL2 (ST6 beta-Galactosamide alpha-2,6-Sialyltranferase 2 (ST6GAL2))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This ST6GAL2 antibody is un-conjugated

Application: Western Blotting (WB)

Clone: RB40602

Product Details anti-ST6GAL2 Antibody

Binding Specificity: AA 483-509, C-Term

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This ST6GAL2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 483-509 amino acids from the C-terminal region of human ST6GAL2.

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Expiry Date: 6 months

References for anti-ST6GAL2 antibody (ABIN1881842)

Lehoux, Groux-Degroote, Cazet, Dhaenens, Maurage, Caillet-Boudin, Delannoy, Krzewinski-Recchi: "Transcriptional regulation of the human ST6GAL2 gene in cerebral cortex and neuronal cells." in: Glycoconjugate journal, Vol. 27, Issue 1, pp. 99-114, (2010) (PubMed).

Ikeda, Tomita, Mouri, Koga, Okochi, Yoshimura, Yamanouchi, Kinoshita, Hashimoto, Williams, Takeda, Nakamura, Nabeshima, Owen, ODonovan, Honda, Arinami, Ozaki, Iwata et al.: "Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic..." in: Biological psychiatry, Vol. 67, Issue 3, pp. 263-9, (2010) (PubMed).

Trynka, Zhernakova, Romanos, Franke, Hunt, Turner, Bruinenberg, Heap, Platteel, Ryan, de Kovel, Holmes, Howdle, Walters, Sanders, Mulder, Mearin, Verbeek, Trimble, Stevens, Kelleher, Barisani et al.: "Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. ..." in: Gut, Vol. 58, Issue 8, pp. 1078-83, (2009) (PubMed).

Krzewinski-Recchi, Julien, Juliant, Teintenier-Lelièvre, Samyn-Petit, Montiel, Mir, Cerutti, Harduin-Lepers, Delannoy: "Identification and functional expression of a second human beta-galactoside alpha2,6-sialyltransferase, ST6Gal II." in: European journal of biochemistry / FEBS, Vol. 270, Issue 5, pp. 950-61, (2003) (PubMed).

Hanna, Kruskal, Ezekowitz, Bloom, Collier: "Role of macrophage oxidative burst in the action of anthrax lethal toxin." in: Molecular medicine (Cambridge, Mass.), Vol. 1, Issue 1, pp. 7-18, (1996) (PubMed).

Target Details for ST6GAL2

Target: ST6GAL2 (ST6 beta-Galactosamide alpha-2,6-Sialyltranferase 2 (ST6GAL2))

Alternative Name: ST6GAL2

Background: Sialyltransferases, such as ST6GAL2 (EC 2.4.99.1), are type II transmembrane proteins that catalyze the transfer of sialic acid from CMP-sialic acid to an acceptor carbohydrate, usually to the terminal ends of carbohydrate chains.

Molecular Weight: 60158

NCBI Accession: NP_001135823, NP_001135824, NP_115917

UniProt: Q96JF0